Jennifer Richer
Concepts (422)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Triple Negative Breast Neoplasms | 16 | 2025 | 191 | 6.790 |
Why?
| Receptors, Androgen | 13 | 2023 | 143 | 5.150 |
Why?
| Breast Neoplasms | 44 | 2024 | 2132 | 3.940 |
Why?
| MicroRNAs | 17 | 2018 | 677 | 3.770 |
Why?
| Androgen Receptor Antagonists | 8 | 2021 | 36 | 2.460 |
Why?
| Anoikis | 7 | 2021 | 32 | 2.260 |
Why?
| Gene Expression Regulation, Neoplastic | 35 | 2025 | 1351 | 2.230 |
Why?
| Tryptophan | 4 | 2024 | 169 | 1.980 |
Why?
| Cell Line, Tumor | 38 | 2025 | 3184 | 1.930 |
Why?
| Estrogen Receptor alpha | 6 | 2022 | 132 | 1.900 |
Why?
| Receptors, Progesterone | 24 | 2016 | 341 | 1.870 |
Why?
| Phenylthiohydantoin | 6 | 2017 | 44 | 1.750 |
Why?
| Tryptophan Oxygenase | 5 | 2024 | 33 | 1.690 |
Why?
| Receptors, Estrogen | 14 | 2020 | 424 | 1.380 |
Why?
| Ovarian Neoplasms | 6 | 2024 | 488 | 1.220 |
Why?
| Progesterone | 16 | 2014 | 242 | 1.020 |
Why?
| Neoplasm Invasiveness | 4 | 2024 | 480 | 1.010 |
Why?
| Progestins | 6 | 2014 | 78 | 0.970 |
Why?
| Tamoxifen | 10 | 2016 | 200 | 0.960 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2024 | 52 | 0.910 |
Why?
| Ribonuclease III | 2 | 2016 | 37 | 0.860 |
Why?
| Neoplastic Stem Cells | 3 | 2017 | 386 | 0.840 |
Why?
| DEAD-box RNA Helicases | 2 | 2016 | 65 | 0.840 |
Why?
| Epithelial Cells | 3 | 2022 | 1032 | 0.830 |
Why?
| Drug Resistance, Neoplasm | 7 | 2020 | 749 | 0.820 |
Why?
| Epithelial-Mesenchymal Transition | 5 | 2018 | 199 | 0.820 |
Why?
| Biomarkers, Tumor | 7 | 2021 | 1181 | 0.810 |
Why?
| Receptor, ErbB-2 | 4 | 2017 | 325 | 0.800 |
Why?
| Cell Proliferation | 14 | 2021 | 2344 | 0.780 |
Why?
| Kallikreins | 1 | 2021 | 29 | 0.760 |
Why?
| Adipokines | 1 | 2021 | 46 | 0.740 |
Why?
| Gene Expression Profiling | 11 | 2018 | 1688 | 0.740 |
Why?
| Neoplasm Recurrence, Local | 6 | 2023 | 958 | 0.720 |
Why?
| Prostate-Specific Antigen | 1 | 2021 | 162 | 0.710 |
Why?
| Endometrial Neoplasms | 6 | 2011 | 164 | 0.700 |
Why?
| Membrane Transport Proteins | 1 | 2021 | 148 | 0.690 |
Why?
| Trophoblasts | 1 | 2022 | 190 | 0.690 |
Why?
| RNA, Long Noncoding | 2 | 2022 | 178 | 0.680 |
Why?
| Immunohistochemistry | 8 | 2017 | 1664 | 0.680 |
Why?
| Transforming Growth Factor beta1 | 1 | 2021 | 154 | 0.670 |
Why?
| Transcription Factors | 13 | 2023 | 1628 | 0.670 |
Why?
| Pulmonary Alveoli | 1 | 2022 | 366 | 0.660 |
Why?
| Cell Movement | 9 | 2020 | 936 | 0.660 |
Why?
| Androgen Antagonists | 3 | 2017 | 79 | 0.660 |
Why?
| Mammary Glands, Animal | 4 | 2022 | 124 | 0.650 |
Why?
| Female | 62 | 2025 | 68153 | 0.650 |
Why?
| Homeodomain Proteins | 5 | 2014 | 490 | 0.630 |
Why?
| Alternative Splicing | 2 | 2018 | 217 | 0.630 |
Why?
| Repressor Proteins | 6 | 2018 | 399 | 0.630 |
Why?
| Cell Cycle | 4 | 2021 | 581 | 0.620 |
Why?
| Up-Regulation | 7 | 2020 | 825 | 0.600 |
Why?
| RNA Splicing Factors | 1 | 2018 | 51 | 0.600 |
Why?
| Humans | 88 | 2025 | 128417 | 0.600 |
Why?
| Mammary Neoplasms, Experimental | 3 | 2017 | 66 | 0.590 |
Why?
| Animals | 39 | 2025 | 34479 | 0.570 |
Why?
| Mice | 24 | 2025 | 16602 | 0.570 |
Why?
| Xenograft Model Antitumor Assays | 8 | 2021 | 814 | 0.550 |
Why?
| Nitriles | 6 | 2017 | 157 | 0.540 |
Why?
| Carcinoma, Endometrioid | 2 | 2008 | 47 | 0.540 |
Why?
| Benzamides | 6 | 2017 | 194 | 0.540 |
Why?
| Gonadal Steroid Hormones | 1 | 2018 | 129 | 0.530 |
Why?
| Lactation | 2 | 2022 | 170 | 0.530 |
Why?
| Lipogenesis | 1 | 2016 | 59 | 0.520 |
Why?
| Paclitaxel | 3 | 2017 | 214 | 0.510 |
Why?
| Antibody Specificity | 1 | 2016 | 182 | 0.510 |
Why?
| Antineoplastic Agents | 6 | 2018 | 2051 | 0.500 |
Why?
| Receptor, trkB | 2 | 2012 | 31 | 0.490 |
Why?
| Receptors, Aryl Hydrocarbon | 1 | 2015 | 51 | 0.480 |
Why?
| Fatty Acid Synthase, Type I | 1 | 2014 | 11 | 0.460 |
Why?
| Apoptosis | 11 | 2020 | 2435 | 0.460 |
Why?
| Kynurenine | 4 | 2024 | 105 | 0.450 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2017 | 380 | 0.450 |
Why?
| RNA Interference | 3 | 2015 | 441 | 0.450 |
Why?
| Antibodies | 1 | 2016 | 391 | 0.450 |
Why?
| Metformin | 2 | 2014 | 312 | 0.430 |
Why?
| Receptors, Steroid | 2 | 2010 | 48 | 0.430 |
Why?
| Tumor Microenvironment | 5 | 2024 | 623 | 0.430 |
Why?
| Gene Expression Regulation | 8 | 2016 | 2505 | 0.410 |
Why?
| Signal Transduction | 18 | 2025 | 4826 | 0.400 |
Why?
| Chromatin | 1 | 2016 | 477 | 0.400 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2018 | 846 | 0.390 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1559 | 0.390 |
Why?
| Neoadjuvant Therapy | 2 | 2020 | 381 | 0.390 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2012 | 66 | 0.380 |
Why?
| Cystadenocarcinoma, Serous | 2 | 2024 | 68 | 0.380 |
Why?
| Sodium-Potassium-Exchanging ATPase | 1 | 2012 | 51 | 0.380 |
Why?
| Antineoplastic Agents, Hormonal | 5 | 2020 | 158 | 0.370 |
Why?
| Disease Progression | 6 | 2018 | 2602 | 0.370 |
Why?
| Endometrium | 2 | 2008 | 61 | 0.360 |
Why?
| NF-kappa B | 3 | 2025 | 649 | 0.350 |
Why?
| Transcriptional Activation | 5 | 2017 | 356 | 0.350 |
Why?
| Mice, SCID | 4 | 2020 | 350 | 0.340 |
Why?
| Cell Transformation, Neoplastic | 1 | 2012 | 325 | 0.330 |
Why?
| Tubulin Modulators | 1 | 2009 | 9 | 0.320 |
Why?
| Estradiol | 6 | 2016 | 486 | 0.320 |
Why?
| Cells | 1 | 2009 | 24 | 0.320 |
Why?
| 3' Untranslated Regions | 4 | 2014 | 140 | 0.320 |
Why?
| Zinc Finger E-box-Binding Homeobox 1 | 4 | 2011 | 22 | 0.310 |
Why?
| Killer Cells, Natural | 2 | 2025 | 426 | 0.310 |
Why?
| Cadherins | 4 | 2012 | 186 | 0.310 |
Why?
| Neoplasms | 5 | 2022 | 2464 | 0.310 |
Why?
| Uterine Neoplasms | 2 | 2008 | 102 | 0.310 |
Why?
| Dirofilaria immitis | 3 | 2010 | 3 | 0.290 |
Why?
| Mice, Nude | 5 | 2017 | 682 | 0.290 |
Why?
| Feedback, Physiological | 2 | 2021 | 74 | 0.280 |
Why?
| Trastuzumab | 2 | 2017 | 100 | 0.270 |
Why?
| Cell Nucleus | 5 | 2017 | 578 | 0.270 |
Why?
| Transfection | 5 | 2012 | 893 | 0.270 |
Why?
| MCF-7 Cells | 3 | 2016 | 115 | 0.270 |
Why?
| Microtubules | 1 | 2009 | 259 | 0.270 |
Why?
| Epidermal Growth Factor | 4 | 2005 | 170 | 0.260 |
Why?
| Anilides | 2 | 2016 | 73 | 0.240 |
Why?
| Mice, Inbred NOD | 3 | 2020 | 586 | 0.230 |
Why?
| Chemokine CCL2 | 1 | 2025 | 118 | 0.230 |
Why?
| Cell Differentiation | 1 | 2012 | 1900 | 0.230 |
Why?
| Down-Regulation | 6 | 2016 | 631 | 0.230 |
Why?
| Microarray Analysis | 2 | 2016 | 120 | 0.230 |
Why?
| Gene Expression | 4 | 2020 | 1456 | 0.230 |
Why?
| Lung Neoplasms | 1 | 2017 | 2328 | 0.220 |
Why?
| Pharmacology, Clinical | 1 | 2023 | 9 | 0.220 |
Why?
| Molecular Targeted Therapy | 2 | 2018 | 385 | 0.210 |
Why?
| Oligonucleotide Array Sequence Analysis | 5 | 2010 | 756 | 0.210 |
Why?
| Mutation | 5 | 2022 | 3689 | 0.200 |
Why?
| Tumor Cells, Cultured | 11 | 2020 | 930 | 0.190 |
Why?
| Milk Proteins | 2 | 1999 | 33 | 0.190 |
Why?
| Mammary Glands, Human | 2 | 2014 | 64 | 0.190 |
Why?
| NF-E2-Related Factor 2 | 1 | 2022 | 67 | 0.190 |
Why?
| Epigenesis, Genetic | 2 | 2018 | 615 | 0.190 |
Why?
| Estrogens | 3 | 2020 | 342 | 0.190 |
Why?
| Epithelium | 1 | 2022 | 306 | 0.190 |
Why?
| Neoplastic Cells, Circulating | 1 | 2022 | 70 | 0.190 |
Why?
| Mice, Transgenic | 2 | 2017 | 2071 | 0.190 |
Why?
| Promoter Regions, Genetic | 6 | 2014 | 1198 | 0.180 |
Why?
| Neoplasms, Second Primary | 1 | 2022 | 108 | 0.180 |
Why?
| DNA-Binding Proteins | 6 | 2018 | 1421 | 0.170 |
Why?
| Neoplasm Proteins | 2 | 2018 | 421 | 0.170 |
Why?
| Semaphorins | 1 | 2020 | 28 | 0.170 |
Why?
| Cytoreduction Surgical Procedures | 1 | 2020 | 61 | 0.170 |
Why?
| Androgens | 1 | 2021 | 173 | 0.170 |
Why?
| Epoxy Compounds | 1 | 2020 | 32 | 0.170 |
Why?
| Gene Knockdown Techniques | 2 | 2020 | 312 | 0.170 |
Why?
| Immune Tolerance | 1 | 2022 | 349 | 0.170 |
Why?
| Respiratory Mucosa | 1 | 2022 | 304 | 0.170 |
Why?
| Transcription, Genetic | 9 | 2012 | 1404 | 0.170 |
Why?
| Carnitine O-Palmitoyltransferase | 1 | 2020 | 45 | 0.170 |
Why?
| Neoplasm Metastasis | 3 | 2025 | 608 | 0.170 |
Why?
| RNA, Messenger | 7 | 2011 | 2675 | 0.160 |
Why?
| STAT5 Transcription Factor | 3 | 2014 | 48 | 0.160 |
Why?
| Chemotherapy, Adjuvant | 1 | 2020 | 376 | 0.160 |
Why?
| Pregnancy | 3 | 2022 | 6357 | 0.160 |
Why?
| RNA, Small Interfering | 3 | 2020 | 571 | 0.150 |
Why?
| Prolactin | 1 | 1998 | 97 | 0.150 |
Why?
| Gene Amplification | 1 | 2018 | 103 | 0.150 |
Why?
| Antigens, CD | 1 | 2020 | 482 | 0.150 |
Why?
| Immunoblotting | 3 | 2010 | 300 | 0.140 |
Why?
| Endometrial Hyperplasia | 2 | 2008 | 11 | 0.140 |
Why?
| Binding Sites | 5 | 2016 | 1236 | 0.140 |
Why?
| Everolimus | 1 | 2017 | 58 | 0.140 |
Why?
| Mammary Tumor Virus, Mouse | 1 | 2017 | 43 | 0.140 |
Why?
| Cluster Analysis | 4 | 2008 | 478 | 0.140 |
Why?
| Fatty Acids | 1 | 2020 | 415 | 0.140 |
Why?
| Dihydrotestosterone | 1 | 2017 | 39 | 0.140 |
Why?
| Immunity, Cellular | 1 | 2018 | 263 | 0.130 |
Why?
| Estrogen Receptor Modulators | 3 | 2008 | 17 | 0.130 |
Why?
| Heterografts | 1 | 2017 | 129 | 0.130 |
Why?
| Neoplasm Transplantation | 2 | 2014 | 258 | 0.130 |
Why?
| Histone Acetyltransferases | 3 | 2006 | 63 | 0.130 |
Why?
| Cyclohexanes | 1 | 2016 | 21 | 0.130 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 210 | 0.130 |
Why?
| Enzyme Inhibitors | 3 | 2024 | 809 | 0.130 |
Why?
| Tumor Suppressor Proteins | 2 | 2014 | 313 | 0.130 |
Why?
| Carcinogenesis | 1 | 2018 | 209 | 0.130 |
Why?
| Trans-Activators | 4 | 2006 | 381 | 0.130 |
Why?
| Placenta | 1 | 2022 | 716 | 0.130 |
Why?
| Hyaluronan Receptors | 2 | 2014 | 97 | 0.120 |
Why?
| Ovary | 1 | 2017 | 210 | 0.120 |
Why?
| Transplantation, Heterologous | 2 | 2014 | 187 | 0.120 |
Why?
| Phosphoproteins | 2 | 2008 | 327 | 0.120 |
Why?
| Hormones | 1 | 2015 | 140 | 0.120 |
Why?
| Drug Delivery Systems | 1 | 2017 | 325 | 0.120 |
Why?
| Tosyl Compounds | 1 | 2014 | 16 | 0.110 |
Why?
| Genes, Reporter | 2 | 2012 | 265 | 0.110 |
Why?
| Ligands | 6 | 2023 | 614 | 0.110 |
Why?
| Protein Transport | 1 | 2015 | 420 | 0.110 |
Why?
| PTEN Phosphohydrolase | 1 | 2015 | 157 | 0.110 |
Why?
| HEK293 Cells | 1 | 2016 | 683 | 0.110 |
Why?
| Sarcoma, Ewing | 1 | 2015 | 87 | 0.110 |
Why?
| In Situ Hybridization | 2 | 2010 | 292 | 0.110 |
Why?
| Disease Models, Animal | 2 | 2021 | 3937 | 0.110 |
Why?
| Cells, Cultured | 2 | 2016 | 4001 | 0.110 |
Why?
| Middle Aged | 7 | 2024 | 30889 | 0.110 |
Why?
| Cellular Reprogramming | 1 | 2014 | 97 | 0.100 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 1993 | 48 | 0.100 |
Why?
| Neurotrophin 3 | 1 | 2012 | 9 | 0.100 |
Why?
| Cell Adhesion | 2 | 2012 | 445 | 0.100 |
Why?
| Clinical Trials as Topic | 1 | 2018 | 993 | 0.100 |
Why?
| Ketones | 1 | 1993 | 47 | 0.100 |
Why?
| Autocrine Communication | 1 | 2012 | 43 | 0.100 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 357 | 0.100 |
Why?
| Aromatase Inhibitors | 2 | 2014 | 51 | 0.100 |
Why?
| Metalloendopeptidases | 1 | 1992 | 59 | 0.100 |
Why?
| Cysteine Endopeptidases | 1 | 1992 | 67 | 0.100 |
Why?
| Nuclear Proteins | 5 | 2000 | 657 | 0.100 |
Why?
| Transduction, Genetic | 1 | 2012 | 128 | 0.100 |
Why?
| Disease-Free Survival | 1 | 2014 | 647 | 0.100 |
Why?
| Gene Silencing | 2 | 2014 | 185 | 0.100 |
Why?
| Mice, Inbred C57BL | 2 | 2016 | 5272 | 0.100 |
Why?
| Carrier Proteins | 2 | 2023 | 732 | 0.090 |
Why?
| Luciferases | 1 | 2012 | 147 | 0.090 |
Why?
| Tumor Burden | 1 | 2012 | 283 | 0.090 |
Why?
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2011 | 5 | 0.090 |
Why?
| Receptors, Leptin | 1 | 2011 | 23 | 0.090 |
Why?
| Tubulin | 1 | 2012 | 137 | 0.090 |
Why?
| Tissue Array Analysis | 2 | 2008 | 57 | 0.090 |
Why?
| Protein Biosynthesis | 2 | 2012 | 397 | 0.090 |
Why?
| GTPase-Activating Proteins | 1 | 2011 | 81 | 0.090 |
Why?
| Predictive Value of Tests | 1 | 2016 | 1935 | 0.090 |
Why?
| Fibronectins | 1 | 2011 | 120 | 0.090 |
Why?
| Microfilament Proteins | 1 | 2011 | 125 | 0.090 |
Why?
| Cell Transdifferentiation | 1 | 2010 | 30 | 0.090 |
Why?
| HeLa Cells | 5 | 2006 | 603 | 0.080 |
Why?
| Retinoid X Receptors | 1 | 2010 | 40 | 0.080 |
Why?
| Cyclins | 3 | 1999 | 85 | 0.080 |
Why?
| Lung | 1 | 2022 | 3743 | 0.080 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2010 | 324 | 0.080 |
Why?
| DNA, Complementary | 4 | 2008 | 267 | 0.080 |
Why?
| Breast | 2 | 2022 | 152 | 0.080 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 940 | 0.080 |
Why?
| Inflammation | 1 | 2020 | 2654 | 0.080 |
Why?
| Protein Isoforms | 4 | 2006 | 378 | 0.080 |
Why?
| Prognosis | 3 | 2024 | 3772 | 0.080 |
Why?
| Cell Line, Transformed | 1 | 2009 | 140 | 0.080 |
Why?
| Receptors, Cytoplasmic and Nuclear | 2 | 2023 | 215 | 0.080 |
Why?
| Aged | 5 | 2024 | 21953 | 0.080 |
Why?
| Reproducibility of Results | 1 | 2016 | 3020 | 0.080 |
Why?
| Perilipin-1 | 1 | 2008 | 16 | 0.070 |
Why?
| Glucose | 1 | 2013 | 982 | 0.070 |
Why?
| S100 Proteins | 1 | 2008 | 36 | 0.070 |
Why?
| Drug Interactions | 1 | 2009 | 357 | 0.070 |
Why?
| Leiomyoma | 1 | 2008 | 74 | 0.070 |
Why?
| Hysterectomy | 1 | 2008 | 118 | 0.070 |
Why?
| Glycoproteins | 2 | 2024 | 337 | 0.070 |
Why?
| Interleukin-6 | 2 | 2024 | 716 | 0.070 |
Why?
| Receptor, IGF Type 1 | 1 | 2006 | 65 | 0.070 |
Why?
| Stem Cells | 1 | 2010 | 578 | 0.060 |
Why?
| Molecular Sequence Data | 6 | 2010 | 2819 | 0.060 |
Why?
| Survival Rate | 2 | 2020 | 1869 | 0.060 |
Why?
| Precancerous Conditions | 1 | 2006 | 161 | 0.060 |
Why?
| Hypoglycemic Agents | 1 | 2013 | 1212 | 0.060 |
Why?
| Thromboplastin | 1 | 2004 | 69 | 0.060 |
Why?
| Neoplasm Staging | 1 | 2008 | 1290 | 0.060 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 1999 | 114 | 0.060 |
Why?
| Obesity | 1 | 2017 | 2858 | 0.060 |
Why?
| B7-1 Antigen | 1 | 2024 | 58 | 0.060 |
Why?
| Protein Binding | 4 | 2010 | 2103 | 0.050 |
Why?
| Ovariectomy | 2 | 2017 | 136 | 0.050 |
Why?
| Neoplasm Grading | 1 | 2024 | 283 | 0.050 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 431 | 0.050 |
Why?
| Postmenopause | 3 | 2017 | 348 | 0.050 |
Why?
| Amino Acid Sequence | 4 | 2010 | 2040 | 0.050 |
Why?
| Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 32 | 0.050 |
Why?
| Immune Evasion | 1 | 2022 | 55 | 0.050 |
Why?
| ErbB Receptors | 1 | 2005 | 601 | 0.050 |
Why?
| B7-H1 Antigen | 1 | 2024 | 189 | 0.050 |
Why?
| Larva | 2 | 1993 | 211 | 0.050 |
Why?
| Adult | 4 | 2016 | 35299 | 0.050 |
Why?
| Biology | 1 | 2022 | 83 | 0.050 |
Why?
| Promegestone | 4 | 2005 | 33 | 0.050 |
Why?
| Fibroblasts | 1 | 2006 | 935 | 0.050 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 181 | 0.050 |
Why?
| Mifepristone | 2 | 2000 | 63 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2004 | 500 | 0.050 |
Why?
| Drug Resistance | 2 | 2000 | 163 | 0.050 |
Why?
| Leukocytes, Mononuclear | 1 | 2024 | 539 | 0.040 |
Why?
| Treatment Outcome | 1 | 2015 | 10151 | 0.040 |
Why?
| Mammals | 1 | 2022 | 268 | 0.040 |
Why?
| Zinc | 1 | 2024 | 292 | 0.040 |
Why?
| GPI-Linked Proteins | 1 | 2020 | 67 | 0.040 |
Why?
| Antigens, Nuclear | 1 | 2000 | 20 | 0.040 |
Why?
| Exons | 2 | 1999 | 338 | 0.040 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2000 | 87 | 0.040 |
Why?
| Young Adult | 1 | 2016 | 12312 | 0.040 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 1999 | 54 | 0.040 |
Why?
| Postpartum Period | 1 | 2022 | 330 | 0.040 |
Why?
| Adenocarcinoma | 1 | 2006 | 888 | 0.040 |
Why?
| Aged, 80 and over | 2 | 2008 | 7033 | 0.040 |
Why?
| Receptor Cross-Talk | 1 | 1998 | 21 | 0.040 |
Why?
| Immunological Synapses | 1 | 2018 | 16 | 0.040 |
Why?
| p300-CBP Transcription Factors | 1 | 2018 | 21 | 0.040 |
Why?
| STAT1 Transcription Factor | 1 | 1998 | 70 | 0.040 |
Why?
| DNA Helicases | 1 | 2000 | 149 | 0.040 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2018 | 133 | 0.040 |
Why?
| Proto-Oncogene Proteins c-fos | 1 | 1998 | 173 | 0.040 |
Why?
| Drug Synergism | 1 | 1998 | 359 | 0.040 |
Why?
| Oxygenases | 1 | 1997 | 10 | 0.040 |
Why?
| Cell Culture Techniques | 1 | 2020 | 345 | 0.040 |
Why?
| Receptor, ErbB-3 | 1 | 2017 | 45 | 0.040 |
Why?
| Biological Transport | 1 | 1998 | 394 | 0.040 |
Why?
| Combined Modality Therapy | 1 | 2020 | 1204 | 0.030 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 1998 | 312 | 0.030 |
Why?
| Carcinogens | 1 | 1997 | 110 | 0.030 |
Why?
| STAT3 Transcription Factor | 1 | 1998 | 190 | 0.030 |
Why?
| Ribosomal Proteins | 1 | 1997 | 77 | 0.030 |
Why?
| Analysis of Variance | 2 | 2005 | 1269 | 0.030 |
Why?
| Steroids | 1 | 2017 | 147 | 0.030 |
Why?
| Muscle, Smooth, Vascular | 1 | 1999 | 417 | 0.030 |
Why?
| Saccharomyces cerevisiae Proteins | 1 | 2000 | 377 | 0.030 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 281 | 0.030 |
Why?
| Oxidation-Reduction | 1 | 2020 | 1001 | 0.030 |
Why?
| Sequence Alignment | 2 | 2010 | 329 | 0.030 |
Why?
| Macrophages | 1 | 2024 | 1460 | 0.030 |
Why?
| Male | 2 | 2021 | 62857 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2017 | 374 | 0.030 |
Why?
| Histones | 2 | 2014 | 586 | 0.030 |
Why?
| Nuclear Receptor Co-Repressor 1 | 3 | 2000 | 16 | 0.030 |
Why?
| Proto-Oncogene Protein c-fli-1 | 1 | 2015 | 23 | 0.030 |
Why?
| Mice, Inbred BALB C | 1 | 2017 | 1228 | 0.030 |
Why?
| Base Sequence | 3 | 2008 | 2135 | 0.030 |
Why?
| Keratin-5 | 1 | 2014 | 49 | 0.030 |
Why?
| Nuclear Receptor Coactivator 1 | 2 | 2006 | 10 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2017 | 659 | 0.030 |
Why?
| Genetic Variation | 1 | 1999 | 933 | 0.030 |
Why?
| Testosterone | 1 | 2017 | 373 | 0.030 |
Why?
| Adipose Tissue | 1 | 2017 | 589 | 0.030 |
Why?
| Dipeptides | 1 | 1993 | 48 | 0.030 |
Why?
| DNA Primers | 2 | 2008 | 510 | 0.030 |
Why?
| Chromatography | 1 | 1992 | 25 | 0.030 |
Why?
| Microscopy, Electron | 1 | 1993 | 417 | 0.030 |
Why?
| Elastin | 1 | 1992 | 77 | 0.020 |
Why?
| Hydrolysis | 1 | 1992 | 184 | 0.020 |
Why?
| Protease Inhibitors | 1 | 1992 | 104 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2020 | 4892 | 0.020 |
Why?
| Blotting, Northern | 1 | 2010 | 198 | 0.020 |
Why?
| Oligopeptides | 1 | 1992 | 256 | 0.020 |
Why?
| Cell Size | 1 | 2010 | 87 | 0.020 |
Why?
| Cell Dedifferentiation | 1 | 2010 | 30 | 0.020 |
Why?
| COS Cells | 2 | 2003 | 184 | 0.020 |
Why?
| DNA, Helminth | 1 | 2010 | 17 | 0.020 |
Why?
| Collagen | 1 | 1992 | 429 | 0.020 |
Why?
| NIH 3T3 Cells | 1 | 2010 | 141 | 0.020 |
Why?
| Electrophoretic Mobility Shift Assay | 1 | 2010 | 83 | 0.020 |
Why?
| Nuclear Receptor Co-Repressor 2 | 2 | 2000 | 15 | 0.020 |
Why?
| DNA Methylation | 1 | 2014 | 604 | 0.020 |
Why?
| Rats | 1 | 2017 | 5165 | 0.020 |
Why?
| Matrix Metalloproteinase 11 | 1 | 2008 | 4 | 0.020 |
Why?
| Phosphorylation | 2 | 2005 | 1681 | 0.020 |
Why?
| Extracellular Matrix | 1 | 1992 | 495 | 0.020 |
Why?
| RNA, Neoplasm | 1 | 2008 | 87 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 2 | 2005 | 1936 | 0.020 |
Why?
| Cell Division | 2 | 2000 | 778 | 0.020 |
Why?
| Myometrium | 1 | 2008 | 35 | 0.020 |
Why?
| DNA, Neoplasm | 1 | 2008 | 159 | 0.020 |
Why?
| Androstadienes | 1 | 2008 | 106 | 0.020 |
Why?
| Trypan Blue | 1 | 2006 | 6 | 0.020 |
Why?
| Comet Assay | 1 | 2006 | 17 | 0.020 |
Why?
| Sequence Analysis, DNA | 1 | 2010 | 771 | 0.020 |
Why?
| Nuclear Receptor Coactivator 3 | 1 | 2006 | 6 | 0.020 |
Why?
| Insulin Receptor Substrate Proteins | 1 | 2006 | 59 | 0.020 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2006 | 67 | 0.020 |
Why?
| Radiation, Ionizing | 1 | 2006 | 75 | 0.020 |
Why?
| Staining and Labeling | 1 | 2006 | 137 | 0.020 |
Why?
| Biomarkers | 1 | 2017 | 3880 | 0.020 |
Why?
| Mutant Proteins | 1 | 2006 | 98 | 0.020 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2006 | 145 | 0.020 |
Why?
| Recombinant Fusion Proteins | 2 | 2000 | 634 | 0.020 |
Why?
| Amino Acid Motifs | 1 | 2006 | 209 | 0.020 |
Why?
| Androstenes | 1 | 2005 | 17 | 0.020 |
Why?
| Caspase 3 | 1 | 2006 | 228 | 0.020 |
Why?
| Medroxyprogesterone Acetate | 1 | 2005 | 35 | 0.020 |
Why?
| Neuroblastoma | 1 | 2006 | 154 | 0.020 |
Why?
| Levonorgestrel | 1 | 2005 | 37 | 0.020 |
Why?
| Protein Structure, Secondary | 1 | 2006 | 338 | 0.020 |
Why?
| Desogestrel | 1 | 2005 | 46 | 0.020 |
Why?
| DNA Repair | 1 | 2006 | 205 | 0.010 |
Why?
| Alkaline Phosphatase | 1 | 2005 | 142 | 0.010 |
Why?
| Sucrose | 1 | 2004 | 94 | 0.010 |
Why?
| DNA Damage | 1 | 2006 | 364 | 0.010 |
Why?
| Insulin-Like Growth Factor I | 1 | 2006 | 307 | 0.010 |
Why?
| Adenosine Triphosphate | 1 | 2006 | 471 | 0.010 |
Why?
| Reactive Oxygen Species | 1 | 2006 | 577 | 0.010 |
Why?
| Protein Structure, Tertiary | 1 | 2006 | 835 | 0.010 |
Why?
| Microscopy, Confocal | 1 | 2004 | 308 | 0.010 |
Why?
| Sequence Homology, Amino Acid | 1 | 2003 | 367 | 0.010 |
Why?
| Progesterone Congeners | 1 | 2002 | 16 | 0.010 |
Why?
| Mutagenesis | 1 | 2003 | 181 | 0.010 |
Why?
| Uterus | 1 | 2003 | 206 | 0.010 |
Why?
| Dimerization | 1 | 2002 | 188 | 0.010 |
Why?
| Cell Survival | 1 | 2004 | 1077 | 0.010 |
Why?
| Plasmids | 1 | 2002 | 354 | 0.010 |
Why?
| Ku Autoantigen | 1 | 2000 | 13 | 0.010 |
Why?
| DNA-Activated Protein Kinase | 1 | 2000 | 15 | 0.010 |
Why?
| Glutathione Transferase | 1 | 2000 | 99 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2003 | 1281 | 0.010 |
Why?
| Antibodies, Monoclonal | 1 | 2006 | 1355 | 0.010 |
Why?
| Culture Techniques | 1 | 1999 | 80 | 0.010 |
Why?
| Methionine | 1 | 2000 | 157 | 0.010 |
Why?
| Estrogen Receptor beta | 1 | 1999 | 35 | 0.010 |
Why?
| Peptide Fragments | 1 | 2003 | 684 | 0.010 |
Why?
| Growth Substances | 1 | 1999 | 150 | 0.010 |
Why?
| Cricetinae | 1 | 1999 | 275 | 0.010 |
Why?
| Phosphotyrosine | 1 | 1998 | 36 | 0.010 |
Why?
| RNA | 1 | 2005 | 880 | 0.010 |
Why?
| Receptors, Growth Factor | 1 | 1998 | 46 | 0.010 |
Why?
| Premenopause | 1 | 1999 | 121 | 0.010 |
Why?
| Sp1 Transcription Factor | 1 | 1998 | 24 | 0.010 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 160 | 0.010 |
Why?
| Chromosome Mapping | 1 | 1999 | 504 | 0.010 |
Why?
| Estrogen Antagonists | 1 | 1998 | 45 | 0.010 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 1998 | 147 | 0.010 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 1998 | 179 | 0.010 |
Why?
| Isomerism | 1 | 1997 | 48 | 0.010 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 1998 | 269 | 0.010 |
Why?
| Gene Deletion | 1 | 1999 | 370 | 0.010 |
Why?
| Leucine Zippers | 1 | 1997 | 16 | 0.010 |
Why?
| Yeasts | 1 | 1997 | 52 | 0.010 |
Why?
| Autoantigens | 1 | 2000 | 416 | 0.010 |
Why?
| Blotting, Western | 1 | 1998 | 1164 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 1998 | 1020 | 0.010 |
Why?
| Time Factors | 1 | 2004 | 6482 | 0.010 |
Why?
| Cell Line | 1 | 1998 | 2731 | 0.010 |
Why?
| Models, Biological | 1 | 1998 | 1691 | 0.010 |
Why?
| Cytokines | 1 | 1999 | 1983 | 0.010 |
Why?
|
|
Richer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|